

# ImiEDC Pilot Implementation at the Department of Obstetrics and Gynecology Heidelberg

André Pfob<sup>1,2,3</sup>, Christian Niklas<sup>4</sup>, Max Blumenstock<sup>4</sup>, Thomas M. Deutsch<sup>1</sup>, Fabian Riedel<sup>1</sup>, Jörg Heil<sup>1</sup>, Martin Dugas<sup>4</sup>, Markus Wallwiener<sup>1</sup>

<sup>1</sup> Department of Obstetrics & Gynecology, Heidelberg University Hospital, Germany

<sup>2</sup> National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany

<sup>3</sup> MD Anderson Center for INSPIRED Cancer Care (Integrated Systems for Patient-Reported Data), The University of Texas MD Anderson Cancer Center, Houston, USA

<sup>4</sup> Institute of Medical Informatics, Heidelberg University Hospital, Germany

(350 word max)

## **Objective:**

ImiEDC is a software that enables digital patient anamnesis and structured documentation of clinical data. We conducted a pilot implementation of ImiEDC at the Department of Obstetrics and Gynecology Heidelberg to evaluate the feasibility of a structured, digital anamnesis.

## **Methods:**

The ImiEDC system was used to create a digital anamnesis questionnaire tailored to patients presenting with ovarian lesions. As of December 21<sup>st</sup> 2022, patients presenting with an ovarian lesion were asked to complete the digital anamnesis questionnaire on an iPad including reason for visit, medical history, and current symptoms.

## **Results:**

Within the first month of the pilot implementation, 26 patients with an ovarian lesion presented at our hospital. Fifteen patients (57.7%) successfully completed the questionnaire and the digital anamnesis was transferred into the electronic data system. The main reasons for not using the digital anamnesis questionnaire were (1) two or more patients presenting at the same time (only one iPad available) and (2) patient wish to use paper-based questionnaire.

## **Summary:**

The ImiEDC system was successfully piloted to enable a structured, digital anamnesis for patients presenting with ovarian lesions. Future evaluations with respect to workflow implications and clinical outcomes are planned.